Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31M&eacute;decins Sans Fronti&egrave;res, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease Epidemiology and Research, University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee JSF, Calmy A, Andrieux-Meyer I, Ford N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/6c808f918c524a758afdb0a759814e85
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c808f918c524a758afdb0a759814e85
record_format	dspace
spelling	oai:doaj.org-article:6c808f918c524a758afdb0a759814e852021-12-02T02:40:39ZReview of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings1179-1373https://doaj.org/article/6c808f918c524a758afdb0a759814e852012-01-01T00:00:00Zhttp://www.dovepress.com/review-of-the-safety-efficacy-and-pharmacokinetics-of-elvitegravir-wit-a9042https://doaj.org/toc/1179-1373Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31M&eacute;decins Sans Fronti&egrave;res, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South AfricaAbstract: Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug&ndash;drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.Keywords: elvitegravir, efficacy, safety, resistance, resource-limited settingsLee JSFCalmy AAndrieux-Meyer IFord NDove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2012, Iss default, Pp 5-15 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Lee JSF Calmy A Andrieux-Meyer I Ford N Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
description	Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31M&eacute;decins Sans Fronti&egrave;res, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South AfricaAbstract: Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requires boosting and this leads to a number of drug&ndash;drug interactions and necessary dose adjustment when dosing with certain drugs, including dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, and lack of data for use in children. Clinical trials addressing specific challenges encountered in resources-limited settings should be encouraged.Keywords: elvitegravir, efficacy, safety, resistance, resource-limited settings
format	article
author	Lee JSF Calmy A Andrieux-Meyer I Ford N
author_facet	Lee JSF Calmy A Andrieux-Meyer I Ford N
author_sort	Lee JSF
title	Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
title_short	Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
title_full	Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
title_fullStr	Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
title_full_unstemmed	Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
title_sort	review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/6c808f918c524a758afdb0a759814e85
work_keys_str_mv	AT leejsf reviewofthesafetyefficacyandpharmacokineticsofelvitegravirwithanemphasisonresourcelimitedsettings AT calmya reviewofthesafetyefficacyandpharmacokineticsofelvitegravirwithanemphasisonresourcelimitedsettings AT andrieuxmeyeri reviewofthesafetyefficacyandpharmacokineticsofelvitegravirwithanemphasisonresourcelimitedsettings AT fordn reviewofthesafetyefficacyandpharmacokineticsofelvitegravirwithanemphasisonresourcelimitedsettings
_version_	1718402292905934848

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Ejemplares similares